Mean body weight reductions after 24 weeks ranged from 8.2% to 10.3% in the MDR-001 cohorts, versus 2.5% in the placebo arm.

Vitable Health, the leading all-in-one health benefits platform redefining care for the American workforce, announced the ...

The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA's recent ...

Patients who took a GLP-1 drug fared better than those in a control group at keeping their blood glucose levels in a healthy ...

A Chinese-developed GLP-1 drug is as effective as Ozempic or Zepbound, clinical trial says ...

A GLP-1 in pill form from Eli Lilly shows promising results for weight loss and Type 2 diabetes treatment in a trial. FDA ...

An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in patients with ...

Hims & Hers delivered record Q1 results and expanded into Europe with the Zava acquisition. Click here to see why HIMS stock is a Hold.

A GLP-1 medication used to treat type 2 diabetes and obesity may help cut a person's monthly migraine days by about half, a ...

With semaglutide and tirzepatide dosed once weekly, their estimated average yearly costs in the U.S. are $14,080 and $8,126, ...

A GP shares her journey using using GLP-1 medication as primary care prescribing of tirzepatide for obesity begins this week.

Lower risks for anxiety disorders, substance use disorders, cognitive deficits seen for those undergoing metabolic and bariatric surgery ...